Table 3.
Polymeric NPs in clinical trials.
| Nanomedicine | Drug | Polymer | Conditions | Reference Clinical Trials |
|---|---|---|---|---|
| Genexol-PM® | Paclitaxel | polymeric micelle formulation | Metastatic adenocarcinoma of the pancreas | NCT02739633 |
| Hepatocellular carcinoma after failure of sorafenib | NCT03008512 | |||
| Advanced urothelial cancer | NCT01426126 | |||
| Advanced non-small-cell lung cancer | NCT01770795 | |||
| Advanced, metastatic and recurrent breast cancer |
NCT01784120 NCT00876486 NCT01169870 NCT00912639 NCT02263495 NCT02064829 |
|||
| Gynecologic cancer | NCT02739529 | |||
| Advanced ovarian cancer |
NCT00877253 NCT01276548 NCT00886717 |
|||
| Advanced and metastatic pancreatic cancer |
NCT00882973 NCT00111904 |
|||
| Advanced non-small-cell lung cancer | NCT01023347 | |||
| Advanced head and neck cancer | NCT01689194 | |||
| Advanced esophageal squamous cell carcinoma |
NCT01474642 NCT00816634 |
|||
| PICN® | Paclitaxel | copolymer polylactide-polyehtylene glycol | Metastatic breast cancer | CTRI/2010/091/001116 |
| BIND-014® | Docetaxel | copolymer polylactide-polyethylene glycol | Metastatic castration-resistant prostate cancer | NCT01812746 |
| Non-small-cell lung cancer | NCT01792479 | |||
| Advanced or metastatic cancer | NCT01300533 | |||
| KRAS positive or squamous cell non-small-cell lung cancer | NCT02283320 | |||
| Urothelial carcinoma, cholangiocarcinoma, cervical cancer and squamous cell carcinoma of the head and neck | NCT02479178 | |||
| Livatag® | Doxorrubicin | Polyalkylcyanoacrylate | Advanced hepatocarcinoma | EudraCT-2006-004088-77 |
| CALAA-01® | siRNA | Adamantane polyethylene glycol containing cyclodextrin | Solid tumor cancers | NCT00689065 |